Axsome Therapeutics Inc (NASDAQ:AXSM)’s share price dropped 36% on Wednesday . The stock traded as low as $3.20 and last traded at $3.55. Approximately 4,146,200 shares changed hands during trading, an increase of 262% from the average daily volume of 1,146,000 shares. The stock had previously closed at $5.55.
A number of research firms recently issued reports on AXSM. Zacks Investment Research upgraded Axsome Therapeutics from a “hold” rating to a “buy” rating and set a $6.50 price objective for the company in a report on Monday, January 1st. Cantor Fitzgerald set a $13.00 price objective on Axsome Therapeutics and gave the company a “buy” rating in a report on Friday, December 1st. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $16.90.
The company has a market cap of $86.53 and a PE ratio of -2.50. The company has a current ratio of 3.86, a quick ratio of 3.86 and a debt-to-equity ratio of 0.44.
TRADEMARK VIOLATION WARNING: “Axsome Therapeutics (AXSM) Stock Price Down 36%” was originally published by Markets Daily and is the property of of Markets Daily. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://www.themarketsdaily.com/2018/01/12/axsome-therapeutics-axsm-stock-price-down-36.html.
Axsome Therapeutics Company Profile
Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain.
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.